AdamsAA, ElzingaS, LymanJ, LittleJ. 2016. Effects of an immunostimulant containing Propionibacterium acnes (EqStim) on cell-mediated immunity and nasal shedding of respiratory pathogens using a model of “weaning”. stress in foals. J Equine Vet Sci, 38:72–81.
KirchnerH, ScottMT, HirtHM, MunkK. 1978. Protection of mice against viral infection by Corynebacterium parvum and Bordetella pertussis. J Gen Virol, 41(1):97–104.
12.
KobusM, LuczakM, SobiczewskaE, SzmigielskiS, JeljaszewiczJ, PulvererG. 1997. Protection and therapy of experimental herpesvirus infections in mice with immunomodulating Propionibacterium avidum KP-40 and/or acyclovir. Zentralbl Bakteriol, 285(3):445–449.
MakNK, SchiltknechtE, AdaGL. 1983. Protection of mice against influenza virus infection: enhancement of nonspecific cellular responses by Corynebacterium parvum. Cell Immunol, 78(2):314–325.
17.
MayrA, BüttnerM, PawlasS, ErfleV, MayrB, BrunnerR, OsterkornK. 1986. Vergleichende Untersuchungen über die immunstimulierende (paramunisierende) Wirksamkeit von BCG, Levamisol, Corynebacterium parvum und Präparaten aus Pockenviren in verschiedenen “in vivo”-und “in vitro”-Testen. J Vet Med Ser B, DOI: 10.1111/j.1439-0450.1986.tb00039.x.
MegidJ, AppolinarioCM, MazziniAM, AlmeidaMF. 2006. Evaluation of cytokines concentration and percentage of survival of rabies virus-infected mice submitted to anti-rabies Vero-cell propagated vaccine and P. acnes. Vet Immunol Immunopathol, 114(1–2):192–196.
20.
MegidJ, CremoniniDN, LeomilH. 2002. Distribution of rabies virus in infected mice, vaccinated and submitted to P. acnes as immunomodulator. Comp Immunol Microbiol Infect Dis, 25(4):237–248.
21.
MegidJ, DiasJJG, AguiarDM, Nardi SilvaWB, RibeiroMG. 2001. Tratamento da Papillomatose Canina com Propionibacterium acnes. Arq Bras Med Vet Zootec, 53:574–576.
22.
MegidJ, KanenoR. 2000. Natural killer activity in mice infected with rabies virus and submitted to P. acnes (Propionibacterium acnes) as immunomodulator. Comp Immunol Microbiol Infect Dis, 23(2):91–97.
23.
MegidJ, KanenoR, NozakiCN, BritoCJ, AlmeidaMF. 2004. Increased interleukin-10 associated with low IL-6 concentration correlated with greater survival rates in mice infected by rabies virus vaccinated against it and immunomodulated with P. acnes. Comp Immunol Microbiol Infect Dis, 27(6):393–411.
24.
MegidJ, PeraçolliMT, CuriPR, ZanettiCR, CabreraWH, VassaoR, ItoFH. 1999. Effect of the bacillus of Calmette-Guérin, Propionibacter acnes and avridine as immunomodulators in antirabies vaccination of mice using the Fuenzalida-Palacios mouse brain vaccine. Vaccine, 17(19):2446–2452.
25.
NaficyK, NateghR, MalekianM. 1971. Antiviral properties of five strains of Corynebacterium. Prog Immunobiol Stand, 5:294–301.
26.
NasserN. 2012. Treatment of common warts with the immune stimulant Propionium bacterium parvum. An Bras Dermatol, 87:585–589.
27.
PaillotR. 2013. A systematic review of the immune-modulators Parapoxvirus ovis and Propionibacterium acnes for the prevention of respiratory disease and other infections in the horse. Vet Immunol Immunopathol, 153(1–2):1–9.
28.
PalmieriB, VadalàM, BondiM, CermelliC. 2020. Propionibacterium acnes: a putative immunemodulating weapon against the coronavirus impending epidemy. Int J Innov Sci Res Technol, 5(2):431–440.
29.
PapaevangelouG, SparrosL, VissoulsC, KyriakidouA, GiokasG, HadzimanolisJ, TrichopoulosD. 1977. The effect of intradermal administration of Corynebacterium parvum on the immune response to hepatitis Bs antigen. J Med Virol, 1(1):15–19.
30.
SchindlerL, StreissleG, KirchnerH. 1981. Protection of mice against mouse hepatitis virus by Corynebacterium parvum. Infect Immun, 32(3):1128–1131.
31.
SzmigielskiS, KobusM, GilJ, JeljaszewiczJ, PulvererG. 1980. Protection and therapy of mice with acute and chronic experimental virus infections with propionibacterium granulosum kp-45. Zentralbl Bakteriol A, 248(3):286–295.
32.
TasakaS, IshizakaA, SayamaK, SakamakiF, NakamuraH, TerashimaT, WakiY, SoejimaK, NakamuraM, MatsubaraH, FujishimaS, KanazawaM. 1996. Heat-killed Corynebacterium parvum enhances endotoxin lung injury with increased TNF production in guinea pigs. Am J Respir Crit Care Med, 153(3):1047–1055.
33.
TeixeiraD, IshimuraME, ApostólicoJdS, VielJM, PassarelliVC, Cunha-NetoE, RosaDS, Longo-MaugériIM. 2018. Propionibacterium acnes enhances the immunogenicity of HIVBr18 human immunodeficiency virus-1 vaccine. Front Immunol, 9:177–177.
34.
VailCD, NestvedAJ, RollinsJB, HuffGK, HartgroveTB, EvansDR, ClapperJJ, Van KampenKR, PetersBA, HayCA. 1990. Adjunct treatment of equine respiratory disease complex (ERDC) with the propionibacterium acnes, immunostimulant, EqStim®. J Equine Vet Sci, 10(6):399–403.
35.
VowelsBR, YangS, LeydenJJ. 1995. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun, 63(8):3158–3165.
36.
WeissRC, CoxNR, Oostrom-RamT. 1990. Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats. Am J Vet Res, 51(5):726–733.
37.
Zgórniak-NowosielskaI, CwikD, SławińskaB. 1989. Protection of mice against vaccinia and herpes simplex virus infection by Propionibacterium acnes. Arch Immunol Ther Exp (Warsz), 37(3–4):431–442.
38.
ZhangB, ChoiYM, LeeJ, AnIS, LiL, HeC, DongY, BaeS, MengH. 2019. Toll-like receptor 2 plays a critical role in pathogenesis of acne vulgaris. Biomed Dermatol, 3(1):4.
